You are here
Israeli biotech firm surges on mystery firm's nameless analyst note
WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.
The two-page report from Acceleron Equity
- CALL +65 6388 3838
- EMAIL firstname.lastname@example.org